Jonathan Broner Selected Research

Jonathan Broner Research Topics

2	Takayasu Arteritis (Arteritis, Takayasu's) 01/2023 - 11/2022
2	Hemorrhage 07/2022 - 01/2021
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 09/2017
2	Vasculitis (Vasculitides) 10/2020 - 09/2017
1	VEXAS syndrome 12/2023
1	Infections 12/2023
1	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2023
1	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2023
1	Churg-Strauss Syndrome (Allergic Angiitis) 12/2022
1	Giant Cell Arteritis (Horton Disease) 05/2022
1	Leukemia 01/2021
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021
1	Thrombophilia 01/2020
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2020
1	Neoplasms (Cancer) 01/2020
1	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 11/2018
1	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 11/2018
1	Arthritis (Polyarthritis) 09/2017

4	tocilizumab (atlizumab)FDA Link 01/2023 - 09/2017
2	Azacitidine (5 Azacytidine)FDA Link 12/2023 - 10/2020
2	GlucocorticoidsIBA 12/2023 - 10/2020
1	Janus Kinase InhibitorsIBA 12/2023
1	EnzymesIBA 12/2023
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2023
1	Interleukin-5 (Interleukin 5)IBA 12/2022
1	AnticoagulantsIBA 07/2022
1	eltrombopag FDA Link 01/2021
1	Inosine Triphosphate (ITP)IBA 01/2021
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2021
1	Antiphospholipid AntibodiesIBA 01/2020
1	Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA 01/2020
1	pembrolizumabIBA 11/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2017
1	Rituximab (Mabthera)FDA Link 09/2017
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 09/2017

3	Therapeutics 07/2022 - 10/2020